Latest Ratios: P/E Ratio -26.8x · EV/EBITDA N/A · ROE -135.6%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9.3B | $9.4B | $461M | $461M | — | — | — | — | — | — | — |
| Enterprise Value | $8.8B | $8.9B | $415M | $267M | — | — | — | — | — | — | — |
| P/E Ratio → | -26.82 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 19.06 | 20.61 | 11.37 | 2.35 | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | -53623.8% | -1409300.0% | -85327.8% | -144970.0% | -11431.5% |
| Operating Margin | — | — | — | — | — | — | -60330.2% | -1664800.0% | -106155.6% | -141500.0% | -14359.1% |
| Net Profit Margin | — | — | — | — | — | — | -59604.8% | -1531700.0% | -87905.6% | -112230.0% | -11266.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -135.6% | -135.6% | -149.0% | -145.4% | -366.8% | -193.7% | -205.8% | -115.1% | -38.2% | -21.4% | -22.3% |
| ROA | -85.2% | -85.2% | -66.2% | -73.4% | -65.7% | -47.0% | -61.0% | -57.9% | -29.3% | -19.6% | -20.9% |
| ROIC | — | — | — | -888.2% | -268.0% | -157.3% | -109.3% | -74.4% | -34.2% | -22.2% | -28.5% |
| ROCE | -77.7% | -77.7% | -98.5% | -96.9% | -128.3% | -64.3% | -83.3% | -78.4% | -40.7% | -26.8% | -28.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 2.40 | 0.30 | 5.45 | 1.99 | 1.90 | 1.12 | 0.31 | — | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.03 | -1.15 | -0.99 | 1.70 | -0.35 | 0.26 | 0.59 | 0.08 | -0.04 | -0.13 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -10.60 | -10.60 | -13.18 | -9.69 | -7.75 | -10.93 | -18.46 | -21.00 | -41.21 | — | -427.05 |
Net cash position: cash ($516M) exceeds total debt ($46M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.75 | 8.75 | 1.84 | 3.25 | 0.70 | 2.33 | 1.94 | 1.47 | 2.47 | 3.84 | 7.85 |
| Quick Ratio | 8.75 | 8.75 | 1.84 | 3.25 | 0.70 | 2.21 | 1.94 | 1.38 | 2.47 | 3.80 | 7.83 |
| Cash Ratio | 8.42 | 8.42 | 1.55 | 2.96 | 0.52 | 1.88 | 1.51 | 0.79 | 1.53 | 3.13 | 6.48 |
| Asset Turnover | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | — | — | — | — | — | 11.38 | — | 24.47 | — | 72.90 | 281.63 |
| Days Sales Outstanding | — | — | — | — | — | — | 46580.95 | 999999.00 | 157619.17 | 133115.50 | 13803.90 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $70M | $63M | $43M | $19M | $15M | $14M | $12M | $10M | $10M | $10M |
Clinical trial binary outcome
Based on reported figures, ABVX trades at a price-to-book ratio of 13.08, which significantly exceeds the valuation of peers like Prothena Corporation, suggesting that investors are pricing in a high probability of success for the obefazimod clinical program rather than current tangible asset value.
The elevated P/B multiple indicates that the market is assigning substantial intangible value to the company's proprietary miR-124 modulation platform. This valuation appears to be a binary bet on clinical outcomes, as traditional earnings-based multiples like P/E are currently non-meaningful due to the company's pre-revenue status.
According to recent financial statements, the company's ROIC has remained consistently negative, reaching -6.3% in 2024Q4, which underscores the significant capital consumption required to advance the ABTECT program without the offsetting benefit of commercial revenue or established operational scale.
The persistent decay in returns on invested capital is a structural feature of the current development phase, where massive R&D outlays are necessary to reach regulatory milestones. Investors should monitor whether these returns can pivot toward positive territory upon potential commercialization, though this remains highly speculative.
As reported in recent filings, the company maintains a current ratio of 7.00 as of 2025Q4, representing a substantial improvement from the 0.77 ratio observed in 2025Q2, which provides a necessary liquidity cushion to fund ongoing Phase 3 clinical trials through their primary data readouts.
This liquidity position appears to be the result of successful capital market activities, effectively mitigating the immediate risk of insolvency. The high ratio suggests that the company is well-positioned to meet its near-term obligations, though the long-term sustainability of this buffer depends entirely on clinical trial progress.
Based on reported figures, ABVX maintains a conservative debt-to-equity ratio of 0.10 as of 2025Q4, reflecting a strategic preference for equity-based financing over debt instruments to avoid interest-related cash outflows during the high-risk, pre-revenue development phase of the business model.
The low leverage profile is appropriate for a clinical-stage biotech firm, as it avoids the burden of debt service during a period of significant cash burn. This structure provides management with greater flexibility to navigate potential clinical setbacks without the immediate pressure of restrictive debt covenants.
Analysts frequently misapply net margin and P/E ratios to ABVX, which obscures the reality that these metrics are currently driven by non-discretionary R&D spending rather than operational inefficiency, warranting a shift toward cash-runway analysis as the primary indicator of the company's financial health.
Using traditional profitability metrics for a pre-revenue entity like ABVX is fundamentally flawed because it treats essential R&D investment as a negative performance indicator rather than a necessary capital allocation. Investors should instead focus on the cash-to-data ratio to assess the company's ability to reach critical clinical milestones.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABVX stock.
Abivax S.A.'s current P/E ratio is -26.8x. This places it at the 50th percentile of its historical range.
Abivax S.A.'s return on equity (ROE) is -135.6%. The historical average is -119.9%.
Based on historical data, Abivax S.A. is trading at a P/E of -26.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.